Hepatitis Delta Virus

Hepatitis Delta Virus (HDV) is a co-infection that affects 5-6% of HBV patients. Compared to HBV infection alone, HBV/HDV co-infected patients are at risk of 2-3x faster onset of both cirrhosis and hepatocellular carcinoma

While there are an estimated 15-70 million HBV/HDV co-infected patients worldwide, HDV is classified as an orphan disease in both the U.S. and EU 1.

The active metabolite of ATI-2173 significantly decreased HDV RNA levels in woodchuck models of HBV/HDV co-infection. Conversely, neither TDF nor ETV have shown activity against HDV in animal models or human studies.

Affects 5-6% of HBV patients
15-70 million HBV/HDV co-infected patients worldwide
Greater risk of cirrhosis and hepatocellular carcinoma
for the treatment of HDV

ATI-2173 is the only ASPIN in development and has significant potential to be a key component of a synergistic combination therapy to cure HBV. Combining ATI-2173 with a chain-terminating NA such as TDF or ETV could shut down the HBV polymerase and all viral replication.

Our Clinical Trials

Antios is conducting a Phase 2a Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection.

Find Out More